Staphylococcus aureus: Resistance update and treatment options

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures

Volumn , Issue , 2007, Pages 75-88

  Moise, Pamela A ^a   Sakoulas, George ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861316273     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. Langmuir AD, Worthen TD, Solomon J, Ray CG, Petersen E. The Thucydides syndrome. A new hypothesis for the cause of the plague of Athens. N Engl J Med 1985; 313(16):1027-30.
2. Olson PE, Hames CS, Benenson AS, Genovese EN. The Thucydides syndrome: Ebola deja vu? (or Ebola reemergent?). Emerg Infect Dis 1996; 2(2):155-6.
3. Peacock SJ, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 2001; 9(12):605-10.
4. Proctor RA. Respiration and small-colony variants of Staphylococcus aureus. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. Gram-Positive Pathogens. Washington D.C.: ASM Press, 2000.
5. Moreillon P, Que YA, Glauser MP. Staphylococcus aureus (including Staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Inc, 2005; 2321-50.
6. Lyytikainen O, Ruotsalainen E, Jarvinen A, Valtonen V, Ruutu P. Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995-2001. Eur J Clin Microbiol Infect Dis 2005; 24(6):399-404.
7. Albrecht SJ, Fishman NO, Kitchen J, et al. Reemergence of Gram-negative health careassociated bloodstream infections. Arch Intern Med 2006; 166(12):1289-94.
8. Falagas ME, Bakossi A, Pappas VD, Holevas PV, Bouras A, Stamata E. Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiol 2006; 6:41.
9. Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KV. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis 2006; 25(8):522-6.
10. Wu CJ, Lee HC, Lee NY, et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J Microbiol Immunol Infect 2006; 39(2):135-43.
11. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23(2):255-9.
12. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3):309-17.
13. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36(1):53-9.
14. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001; 175(5):264-7.
15. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163(17):2066-72.
16. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32(8):470-85.
17. Johnston BL. Methicillin-resistant Staphylococcus aureus as a cause of communityacquired pneumonia-a critical review. Semin Respir Infect 1994; 9(3):199-206.
18. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12(6):894-9.
19. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16(Suppl. 1):S31-4.
20. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50(6):1017-26.
21. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43(13):925-42.
22. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171(4):388-416.
23. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166(19):2138-44.
24. Scheinfeld N. Dalbavancin: a review for dermatologists. Dermatol Online J 2006; 12(4):6.
25. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs 2006; 7(8):740-9.
26. Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 2006; 4(5):743-9.
27. Page MG. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006; 6(5):480-5.
28. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006; 12(Suppl. 2):17-22.
29. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004; 64(4):445-55.
30. Barriere JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, Desnottes JF. Recent developments in streptogramin research. Curr Pharm Des 1998; 4(2):155-80.
31. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41(10):2132-6.
32. Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 44(Suppl. A):31-6.
33. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21(3):263-74.
34. Willke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int J Technol Assess Health Care 2002; 18(3):540-54.
35. Pegues DA. Daptomycin: a viewpoint by david a. Pegues. Drugs 2004; 64(4):457-8.
36. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355(7):653-65.
37. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43(7):1549-55.
38. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31(8):481-98.
39. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46(8):2723-6.
40. Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53(6):1114-5.
41. McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25(1):18-21.
42. Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am J Ophthalmol 2005; 139(6):1114-6.